论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Wang J, Wang Y, Tong M, Pan H, Li D
Received 11 July 2018
Accepted for publication 19 September 2018
Published 16 October 2018 Volume 2018:11 Pages 7011—7017
DOI https://doi.org/10.2147/OTT.S179904
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Samir Farghaly
Abstract: Adenosquamous carcinoma (ASC) of the lung, a biphasic malignant tumor
arising from lung tissue, is a special subtype of non-small-cell lung cancer
(NSCLC) with low incidence but high tendency of invasion and poor prognosis.
ASC contains components of lung adenocarcinoma (AC) and lung squamous cell
carcinoma (SCC). However, there is a remarkable difference between ASC and
other NSCLCs in clinical features, suggesting that ASC is not a simple mixture
of AC and SCC, but is rather a more complex carcinoma with a unique molecular
phenotype. At present, the research on ASC is still rare, mostly because of its
complicated molecular mechanism and unclear pathological origin. The lack of
cognition of ASC limits its early diagnosis and treatment, and a set of mature
and effective treatment programs has not been proposed yet. In-depth study of
the molecular characteristics and clinical features of ASC will not only help
to better understand the scientific issues, including phenotype switching of
lung cancer, the origin of tumor development, and tumor heterogeneity, but also
contribute to the development of its individualized treatment. This review
summarizes the recent studies concerning the clinicopathologic features and the
molecular mechanisms of ASC to further facilitate the development of its individualized
treatment.
Keywords: lung adenosquamous carcinoma, lung adenocarcinoma, lung squamous cell
carcinoma, prognostic factor, clinicopathologic features